These data follow on the arguably more important results that we got earlier this month of how Lilly's pill fared in people diagnosed with obesity. The latest ones are people with obesity and Type two diabetes. That initial reaction was one of pretty massive disappointment.Lilly had its worst day in about two decades and lost about $100 billion in market value. So today's improvement kind of has to be viewed in that context. But I think zooming out, as Matt mentioned, this is the final hurdle they had to cr ...